CAJ | 학술논문

目的：观察恩替卡韦联合心肝宝治疗慢性乙型肝炎肝硬化的临床疗效。方法将本院2010年5月-2013年10月收治的60例慢性乙型肝炎肝硬化患者随机分为2组，治疗组（30例）给予恩替卡韦联合心肝宝胶囊治疗，对照组（30例）只给与恩替卡韦治疗，疗程均为6个月。观察2组治疗前后肝功能、血清纤维化指标和肝、脾影像学等项目。计量资料组间比较采用t检验，计数资料组间比较采用χ2检验。结果治疗组ALT、AST与对照组相比差异有统计学意义（P＜0．05），血清纤维化指标，肝、脾影像学检查有显著改善（P＜0．01）。结论恩替卡韦联合心肝宝治疗慢性乙型肝炎肝硬化，具有改善肝功能，减轻肝组织炎症；抗肝纤维化，降低门静脉压力和缩脾作用。
목적：관찰은체잡위연합심간보치료만성을형간염간경화적림상료효。방법장본원2010년5월-2013년10월수치적60례만성을형간염간경화환자수궤분위2조，치료조（30례）급여은체잡위연합심간보효낭치료，대조조（30례）지급여은체잡위치료，료정균위6개월。관찰2조치료전후간공능、혈청섬유화지표화간、비영상학등항목。계량자료조간비교채용t검험，계수자료조간비교채용χ2검험。결과치료조ALT、AST여대조조상비차이유통계학의의（P＜0．05），혈청섬유화지표，간、비영상학검사유현저개선（P＜0．01）。결론은체잡위연합심간보치료만성을형간염간경화，구유개선간공능，감경간조직염증；항간섬유화，강저문정맥압력화축비작용。
Objective To observe the clinical efficacy of entecavir combined with Xinganbao capsules in the treatment of liver cirrhosis a-mong patients with chronic hepatitis B (CHB).Methods Sixty CHB patients with liver cirrhosis were randomly divided into two groups:treatment group (n=30)given entecavir combined with Xinganbao capsules and control group (n=30)given entecavir alone.The course of treatment was 6 months.The treatment outcomes were evaluated based on liver function,serum fibrosis markers,and imaging findings of the liver and spleen.Comparison of continuous data between groups was made by t test,while comparison of categorical data was made by chi-square test.Results After treatment,the treatment group had significantly lower serum levels of alanine aminotransferase and aspar-tate aminotransferase (P<0.05),significantly reduced serum fibrosis markers (P<0.01),and significantly improved imaging findings of the liver and spleen (P<0.01),as compared with the control group.Conclusion Entecavir combined with Xinganbao capsules can im-prove liver function,reduce hepatic inflammation and fibrosis,and decrease portal pressure and spleen thickness in the treatment of liver cir-rhosis among CHB patients.